key: cord-0779636-812qirew
authors: Ridgway, Harry; Moore, Graham J.; Mavromoustakos, Thomas; Tsiodras, Sotiris; Ligielli, Irene; Kelaidonis, Konstantinos; Chasapis, Christos T.; Kate Gadanec, Laura; Zulli, Anthony; Apostolopoulos, Vasso; Petty, Russell; Karakasiliotis, Ioannis; Gorgoulis, Vassilis G.; Matsoukas, John M.
title: Discovery of a new generation of angiotensin receptor blocking drugs: receptor mechanisms and in silico binding to enzymes relevant to covid-19
date: 2022-04-09
journal: Comput Struct Biotechnol J
DOI: 10.1016/j.csbj.2022.04.010
sha: af988a322e0bdc68bcc75342f6a608c60adafc95
doc_id: 779636
cord_uid: 812qirew

The discovery and facile synthesis of a new class of sartan-like arterial antihypertensive drugs (angiotensin receptor blockers [ARBs]), subsequently referred to as “bisartans” is reported. In vivo results and complementary molecular modelling presented in this communication indicate bisartans may be beneficial for the treatment of not only heart disease, diabetes, renal dysfunction, and related illnesses, but possibly COVID-19. Bisartans are novel bis-alkylated imidazole sartan derivatives bearing dual symmetric anionic biphenyl tetrazole moieties. In silico docking and molecular dynamics studies revealed bisartans exhibited higher binding affinities for the ACE2/spike protein complex (PDB 6LZG) compared to all other known sartans. They also underwent stable docking to the Zn2(+) domain of the ACE2 catalytic site as well as the critical interfacial region between ACE2 and the SARS-CoV-2 receptor binding domain. Additionally, semi-stable docking of bisartans at the arginine-rich furin-cleavage site of the SARS-CoV-2 spike protein (residues 681-686) required for virus entry into host cells, suggest bisartans may inhibit furin action thereby retarding viral entry into host cells. Bisartan tetrazole groups surpass nitrile, the pharmacophoric “warhead” of PF-07321332, in its ability to disrupt the Cysteine Charge Relay System of 3CLpro. However, despite the apparent targeting of multifunctional sites, bisartans do not inhibit covid infection in bioassays as effectively as PF-07321332 (paxlovid).

This study has been undertaken with the knowledge that cardiovascular disease is related to COVID-19 in terms of mechanisms that trigger the disease 1 . The storm of cytokines released in COVID-19 patients with pneumonia is related to the overexpression of toxic angiotensin II in the renin-angiotensin system (RAS) and clinical studies have shown that morbidity and mortality rate was lower in hypertensive patients infected by SARS-CoV-2, who are taking angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) compared to patients not taking these drugs. Angiotensin II, the major RAS component, and SARS-CoV-2 spike protein cleavage by furin and 3CLpro that initiate infection operate through similar charge relay system mechanisms 2 . Tyrosinate in angiotensin II, serinate in furin, and cysteinate in 3CLpro are anions created through the charge relay system mechanism and trigger activity via their nucleophile anions. Bisartans bearing two biphenyl tetrazole moieties were found in silico studies to be stronger inhibitors compared to current sartans 3 . Similar charge relay system mechanisms spark and mediate the action of angiotensin II 4 and the serine-like proteases furin and 3CL 2 .

Two states of the AT1 receptor, agonist and inverse agonist states, interact, respectively, with surmountable and insurmountable angiotensin II (ANG II) nonpeptide angiotensin receptor blockers (ARBs). Neutralization of tyrosinate in the ANG II analog [Sar 1 Ile 8 ]ANG II (sarilesin) (by methylation) or the conversion of hydroxymethyl group to carboxylate in ARBs (e.g. losartan to EXP3174), converts inverse agonist to a surmountable antagonist in both cases, thus illustrating equivalent roles for peptide tyrosinate and ARB carboxylate at angiotensin receptors.

inverse agonists appears to depend on the nature of the bond (i.e., ion:dipole versus salt bridge) that forms with R167 of the receptor. These insights have provided the foundation for a new class of ARBs called bisartans with bis-alkylated imidazole bearing two tetrazoles moieties essential for binding with arginines of the Delta mutations of COVID-19. This class may be beneficial in the treatment of SARS-COVID-19 infection as it has the most suitable structural requirements between AT1

antagonists.

Biased agonism at angiotensin II receptors: The interaction of angiotensin II (ANG II) with its G protein-coupled angiotensin type 1 receptor (AT1) receptor in receptor bound to nonpeptide receptor blockers (ARB) illustrates that the inverse agonism of ARBs derives primarily from a salt bridge between ARB carboxylate and R167 guanidino on the receptor. This locks the receptor into an inverse agonist state mediated by an alternative second messenger, which is slow to reverse.

Neutralization of tyrosinate in sarilesin (by methylation) or the oxidation of hydroxymethyl group of Losartan to carboxylate to derive EXP3174 converts inverse agonists to surmountable antagonists in both cases. These simple chemical modifications highlight equivalent roles for peptide tyrosinate and ARB carboxylate at angiotensin receptors. A charge relay system (CRS; composed of Tyr--His--carboxyl) in ANG II, which creates the bioactive tyrosinate anion essential for agonist [and inverse agonist] activity, may activate the receptor by CRS exchange of the Tyr 4 of ANG II with Y35 of the receptor. The behavioural bias of agonists and surmountable antagonists versus inverse agonists ultimately depends on the nature of the bond (i.e., ion:dipole bond versus salt bridge) that Ang II forms with R167 of the receptor.

Screening of the human genome has identified a peptide (EGVYVHPV) encoded by mRNA complementary to that encoding ANG II itself, which is a naturally occurring inverse agonist 5 with ANG II and mutants involving four residues D, Y, H, and the C-terminus carboxylate has been recently reported 6 in line with the coordination of spike/ACE2 Zn+2 with bisartans shown in our studies. We sought and identified new ANG II inhibitors that possess a high binding affinity to ACE2 using computational methods.

Bisartans A, B, C, and D bear two acidic tetrazoles, which are isosteres of carboxylates, are able to inhibit the interaction between the spike protein of the virus and ACE2 without abolishing the ability of the enzyme to reduce ANG II levels, a beneficial factor in the renin-angiotensin system (RAS) to maintain homeostasis and equilibrium of RAS components. Bisartans were found to be stronger binders to the RBD/ACE2 complex compared to current sartans and represent a promising new class of synthetic and cost-effective bioactive antihypertensive drugs that concomitantly act at multiple sites required for SARS-CoV-2 infection, with particular relevance for the Delta variant and furin cleavage site, both arginine-rich.

Furthermore, bisartans may act at multiple sites [with higher affinity than existing drugs] and have advantages over antibody treatments because they don't discriminate significantly between variants of COVID-19. Bisartan A attacks all three of the known target proteases which COVID-19 requires for cell entry (ACE2 and furin) and viral maturation (3CLpro), and is the first potent multifunctional drug which is a serial inhibitor of multiple enzymes essential for COVID-19 activity. Although bisartan has the added [and useful] quirk of increased affinity for [the arginine-rich site on the spike protein of] the delta variant, in general drugs like bisartan, which act as proteolytic inhibitors at both the host cell and viral cell level, should not discriminate meaningfully between variants -unlike antibody treatments which are highly selective for site-specific sequences on the viral spike protein. Accordingly, drugs like bisartans may prove advantageous because they are broad-spectrum [and immediate] treatments against a continuously changing COVID-19 virus. Bisartans A, B, C, D have been found in in silico studies to bind to 3CL protease and to be stable as Pfizer's Paxlovid combination drugs (PF-07321332 and Ritonavir) where nitrile is the warhead pharmacophoric group of antiviral PF-07321332 drug 7, 8, 9, 10 . However, despite the apparent targeting of multifunctional sites uncovered in silico, Bis D nitrile does not inhibit covid-19 infection in bioassays, whereas Bis D tetrazole invokes 20% inhibition (compared to PF-07321332 at 95%). Bisartans bearing two pharmacophoric tetrazole groups that interact with Cys145 of the catalytic dyad, His41-Cys145, make inoperable the cysteine Charge Relay System protease mechanism of spike cleavage thus preventing infection. However, despite the apparent targeting of multifunctional sites uncovered in silico, bisartans BisA (tetrazole and nitrile) and BisD (tetrazole and nitrile) do not inhibit covid-19 infection in bioassays.

The octapeptide angiotensin ANG II (DRVYIHPF), a model for hormonereceptor interactions 4 , acts on the AT1 receptor in smooth muscle and other tissues, resulting in contraction and elevated blood pressure. Lowering ANG II levels with ACE1 inhibitors or direct inhibition with ARBs provides effective treatment of hypertension. ARBs demonstrated insurmountable blocking effects at AT1 receptors, which are similar to the effects seen with certain synthetic analogs of ANG II in which the C-terminal Phe is replaced by an aliphatic amino acid, such as Ile. Initially, sarilesin was designed as a Type I desensitizing antagonist, differing from competitive surmountable Type II antagonists like [Sar 1 Tyr(Me) 4 ]ANG II (sarmesin).

This was due to its effects being insurmountable (i.e. lasting long after washout of tissues) and reminiscent of the desensitization/tachyphylaxis caused by supramaximal doses of the agonist. However, detailed investigation of doseresponse data, transformed into Hanes-Wolff and Hill plots 11 , has shown that sarilesin induces negative cooperatively (Hill coefficient n H <1), thus, signifying negative efficacy, which is synonymous with inverse agonism (Table 1B) (Table 1B) . Whereas, submaximal doses of ANG II resulted in positive cooperativity (n H >1<2), initiating receptor dimerization with a consequent increase in affinity for ANG II 12 . Additionally, supramaximal doses of ANG II can invoke negative cooperativity and tachyphylaxis ( Figure 1B ). Hill coefficients also revealed differences in tissue responsiveness to ANG II, with receptor avidity in the order aorta > portal vein > uterus (Table 1A) . The prolonged effect of sarilesin does not appear to be due to slow ligand dissociation rate from the receptor, as bindingdisplacement curves for 125I-ANG II and 125I-[Sar 1 Ile 8 ]ANG II are superimposable.

The receptor may likely may be locked down as a result of slow dissociation of the second messenger, which is coupled to the "inverted" state of the receptor ( Figure   1B 14 . and B are weaker binders to RBD/ACE2 complex compared to bisartan A ( Figure 2A and Figure 3A ), since they bear at the imidazole C2 carbon substituents, hydroxyl methyl and butyl group correspondingly, which interfere between the two biphenyl tetrazole groups that bind to ACE2 or AT1R, therefore, reducing their binding affinity.

In a similar mode, bisartan A was found in in vitro assays ( Figure 1A ) to be a stronger binder with higher affinity (-logIC 50 interactions, however, the diphenyl groups showed significant hydrophobic interactions with fairly close residues, particularly Pro168 ( Figure 8 ). Although BisA did not appear to interact directly with Cys145. However, the distance between a tetrazole of BisA and the Cys145 residue is less than 4 A, suggesting a weak interaction.

Bisartans tetrazole and PF-0732133 nitrile groups are the pharmacophoric warheads of the two inhibitors to disrupt the Cys CRS catalytic center of 3CLpro preventing spike protein cleavage and infection. Bisartans have been found in in silico studies to be binders to protease 3CLpro catalytic center and stable in MD simulations ( Figure 9 ).

Therefore to further test the functioning roles and compare tetrazole and nitrile the two principal structural factors in the two drugs that interact with Cys145 of the catalytic dyad, Cys145 -His41, we compared bisartan A tetrazole and bisartan A nitrile, where tetrazole was replaced by nitrile, by additional docking (Figure 9 ). The docking results showed that bisartans tetrazole have higher binding energy compared to bisartan nitrile and bisartan nitrile has higher binding energy compared to PF-0732133 ( Figure 2C ) which indicate an additional contributing role for the biphenyl group of bisartans in the inhibition furthermore to the tetrazole moiety.

To determine if the newly formulated bisartans mimic the effect of ARBs, iliac artery rings collected from rabbits were incubated with bisartan A (K + ) 2 , bisartan A (Na + ), and bisartan A (TFA). To evaluate the ability of these drugs to inhibit vascular smooth muscle cell constriction an ANG II dose-response assay was performed, and results were compared to untreated control rings. Vasoconstriction responses to cumulative doses of ANG II in iliac rings were potently inhibited by all bisartan A salts investigated (Table 1A) . Vasoconstriction was potently inhibited by: bisartan A (K + ) 2 that the novel bisartans may act as ARBs by exerting their effects through association and inhibition of AT1R function with low drug concentrations. Figure 2A depicts the Inhibitory effect of the novel bisartan A salts, bisartan A (K + ) 2 , bisartan A (Na + ), and bisartan A (TFA) on ANG II-induced vasoconstriction responses in rabbit iliac arteries.

The replacement of the C-terminal Phe residue of ANG II with an aliphatic amino acid (Ile, Leu, Val, Ala) converted the molecule to an analog with

[insurmountable] inverse agonist properties. It was of interest to investigate if such a molecule could predicate a naturally occurring product encoded by the human genome, designed to counteract ANG II. The sequence of human mRNA which is complementary to that for ANG II 5 was found to encode the ANG II analog EGVTVHPV, and likewise the ANG III analog GVTVHPV. The C-terminal Val residue conferred insurmountable antagonist properties to these "antipeptides", whereas the absence of the Arg side chain at position 2 has only modest effects on activity.

Accordingly, this angiotensin antipeptide was produced as a natural countermeasure to ANG II, by binding to the inverse agonist site ( Figure 1B ). Interestingly, RNA sequences encoded peptides with opposite actions. ANG II has a fundamental role in the regulation of cardiovascular function and its actions are controlled at multiple levels, including gene expression and enzymatic biosynthesis of components of the RAS. This gives rise to ANG II metabolism by ACE2, resulting in the vasodilator peptide angiotensin 1-7, which associates with AT2 receptors, as well as signaling effects at AT1 receptors. The present findings add yet another potential level of control for physiological regulation of the RAS via the production of endogenous antipeptides acting directly as inverse agonists at AT1 receptors.

COVID-19 patients often present with compromised lung function due to severe pulmonary edema 15 

We have developed a new generation of ARBs, called bisartans 29 , the structures of which include two tetrazole groups. As previously discussed, tyrosinate in sarilesin and carboxylate in EXP3174 were both effective at creating salt bridges with R167. We wanted to determine if tetrazolate, which is a functional mimetic of carboxylate, might also suffice. By using imidazole as the template for mounting two biphenyl tetrazole groups, we conjectured that the resulting positive charge on the imidazole may be the correct distance from the two tetrazoles to subsume the space normally occupied by the Arg 2 guanidino group of ANG II when the peptide is bound to the receptor (Arg2 is predicted to interact with D263 and D281 of the receptor) 30 .

Results determined that bisartans are potent insurmountable antagonists of AT1 receptors 31 , and are the first ARBs discovered that do not use a carboxylate for binding to Arg167. Instead, bisartans use a second tetrazolate to form the critical salt bridge with Arg167, which appears to provide for insurmountable activity ( Figure 1B ).

This study complements results from previously published literature 31 by demonstrating the ability of bisartans to act as ARBs through interactions with the AT1 receptor by inhibiting constriction in response to ANG II. An ANG II doseresponse was performed on Iliac artery rings collected from male New Zealand White rabbits subsequent to incubation with the following bisartan A salts: BV6(K + ) 2 , BV6(Na + ), and BV6(TFA). Results from this study determined that bisartan A salts were able to potently abolish ANG II-induced vasoconstriction (Table 1A and Figure   2A ). Bisartans likely exhibit significant bioactivity at AT1 receptors because of tight binding to R167 due to the particular geometry of the double tetrazole unit surrounding the R167 guanidino group. Essentially, bisartan can enfold the R167 guanidino group in the tight embrace of two tetrazole moieties ( Figure 10 ). In addition to their properties as potent ARBs, bisartans are expected to be inhibitors of zinc proteases, such as ACE2. Zinc proteases are inhibited by chelating agents, which bind to the zinc atom at the active site of this class of enzymes. For example, ACE2

can be completely inhibited by the chelating agent 1,10-phenanthroline 31 , which due to the juxtaposition of its two nitrogens, can have a bivalent interaction with zinc.

Likewise, bisartans contain two powerful chelators in the form of anionic tetrazole groups, which can effectively embrace the zinc atom at the active site of zinc proteases like ACE2 in a quadrivalent interaction, as was observed in docking models for BisD in particular (see Figure 5 , Figure 10 and Figure Inhibition of ACE2 enzyme activity may be due to allosteric interference with the binding of SARS-COVID-19 spike protein to ACE2, even though the proteolytic site is distant from the spike RBD, and therefore may only partially inhibit entry of the virus into the cell. There is also the possibility that bisartans could attach to the furin cleavage site PRRARS (residues 681-686 of spike protein), due to the preponderance of Arg residues (as per Figure 10B ), which gives rise to subunits S1 and S2. These subunits assist in the viral cell entry process, offering an additional potential mechanism for inhibiting the virus 32, 33 . A mutation at P681R in the cleavage 

Burgeoning evidence from chemical reactivity, structure-activity, NMR, and fluorescence lifetime studies 13, 29, 40, 41 suggest that activation of AT1 receptors may be driven by the formation of a charge relay system (CRS) in ANG II, encompassing

TyrOH --His --carboxylate (analogous to serine proteases) 2 , which generates tyrosinate anion species for activating the receptor ( Figure 10F) The first nonpeptide ARB to be discovered was the surmountable antagonist losartan, which is metabolized to the [insurmountable] inverse agonist EXP3174 in the bloodstream ( Figure 10D Figure 9A ) 42, 43, 44 . The salt bridge between R167 and carboxylate is solely responsible for the insurmountable effects of ARBs, as evident by surmountable losartan. Similarly, the peptide antagonist sarmesin cannot form this salt bridge but can form a weaker ion: dipole bond, same as losartan, and is therefore a surmountable antagonist. In contrast, the peptide sarilesin is able to form the necessary salt bridge between its tyrosinate anion and R167 and is therefore an insurmountable inverse agonist (Table 1B) . Methylation of the TyrOH of sarilesin converts this peptide from insurmountable to surmountable antagonist, as expected.

The main role of the CRS in ANG II is the creation of two partial negative charges, TyrOand CO 2 -, the spacing of which is reproduced by the two acid groups in insurmountable ARBs ( Figure 11B ). This is the only way the superagonist [Sar 1 ]ANG II, which contains a single naked anion, can achieve a two-point attachment to the receptor. These partial anion pairs in ANG II can form salt bridges with Arg167 and Lys199 of the receptor in a similar manner to ARBs ( Figure 10G and Figure 11B and C). It follows that if Y35 is close enough to form a bond with the imidazole N of ARB ( Figure 8B and C), then it must also be in the right place to potentially interact with the imidazole N of His 6 in ANG II ( Figure 11A , B, and C).

Therefore, receptor activation may be driven by a charge relay exchange mechanism between peptide and receptor ( Figure 8A , B and C), wherein the The receptor dynamic may be characterized by competition between the two tyrosines of receptor and ANG II. For agonist activity, the G protein-linked receptor dimerization process, which results in amplification of the contractile response, requires the presence of the Phe 8 ring of ANG II, which is notably absent in ARBs.

Accordingly, the triggering process may also require interaction of the Phe 8 ring with the ring of Y35 of the receptor ( Figure 10G and Figure 11B and C), an interaction that is not feasible for insurmountable Sarilesin. Clustering of the aromatic rings of ANG II has been observed by NMR 40, 41 , which may be reproduced at the receptor, but with Y35 substituting for Tyr4 of ANG II (see Fig. 7 

which is based on the quadrupole moments of aromatic rings, may be reinforced by the preexisting Phe:His ring interaction in ANG II (see Fig. 8 B and C for details), and part of a concerted mechanism involving G protein binding/receptor dimerization 29 for activating AT1R. In contrast, selectivity for AT2R GPCR invokes [Y6]ANG II which is a negative regulator of AT1R signaling 45 .

Also, W84 of the receptor interacts with the imidazole of ARBs 42, 43 and by inference may bond with the His 6 ring of ANG II, suggesting that there is ring stacking of Y35. In stark contrast to ANG II, the binding of ARB to the receptor is static ( Figure   11B and C) involving a strong salt bridge with R167, rendering it unable to stimulate G protein binding and receptor dimerization required for the contractile response. The same considerations apply to sarilesin because the electrostatic properties of aromatic rings prevent interaction of the hydrophobic Ile 8 side chain of sarilesin with either His 4 of ANG II or Y35 of the receptor, deeming these interactions necessary for agonist activity ( Figure 11A , B and C). Sarilesin and ARBs (e.g. EXP3174) form a stable salt bridge with R167 and act as insurmountable ligands/inverse agonists.

Moreover, the inverted receptor state binds a second messenger, which invokes a relaxation response. The exact identity of this messenger is not known; however, possible candidates include B-arrestin, bradykinin receptor or a different G protein 42, 43 .

Knowledge from previous studies have allowed the construction of this model for angiotensin action ( Figure 11B and C), which is entirely consistent with known facts, namely SSMs effects on activity and the crystal structure of AT1 bound to ARB 42, 43 show that (i) Y35 is essential for binding of ARBs and ANG II; which cleaves the R685-S686 bond. However bisartans are less potent than PF-07321332 in covid-19 bioassays (Fig.15 ). Bisartans block the furin catalysis of spike protein which occurs through a charge relay system mechanism involving the triad Asp-His-Ser. Therefore, we thought to test if bisartans block as well 3CL protease which cleaves spike protein in a similar charge relay system mechanism through dyad His41-Cys145 which is the catalytic center of the protease. We compared our bisartans with Pfizer's new oral drug PF-07321332 which blocks the spike cleavage through the nitrile group, the warhead of the drug which disrupts the cleavage mechanism. Bisartan A was found to bind to 3CLpro stronger than PF-07321332 and to be more stable (Figure 7 and Figure 8 ). Overall, bisartans block the spike cleavages through the three cell entries (ACE2, furin, 3CLpro) rendering them promising drugs for clinical trials.

General conclusions which can be drawn from MD and the docking studies are 1) that bisartans bind strongly to 3-CL protease active site, 2) bisartans have higher affinities than ligands containing nitrile, namely PF07321332 and bisartannitrile, 3) the tetrazole and nitrile "warheads" of these ligands appear to be close enough to Cys145 thiol to form a (transient) covalent, and 4) bisartans have the added desirable property of interfering with the ACE2/SPD interaction in addition to 3-CL protease. It is also possible that bisartans, due to their zwitterionic nature, do not readily permeate membranes, and demonstrate reduced covid bioassay inhibition due to poor cell permeation/access.

In 

The synthesis of Bisartan A was a two-step procedure: a) bis-alkylation of 4(5) butyl imidazole using alkylating reagent 4'-(bromomethyl)-[1,1'-biphenyl]-2-(trityl)tetrazol, b) removal of trityl chloride group with novel methods described earlier 3 . Bisartan B was synthesized by formylation of bisartan A at position 2 using 37% formalin and diisopropylethylamine in DMF at 80 o C for 1h. In bisartans A and B, the butyl group is at position 4 which is favourable for better binding of this lipophilic group with the hydrophobic cleft site of the AT1 receptor. Bisartan C was synthesized by alkylation of Losartan analogs as previously described 3 where the butyl group is at position 2 which is less favourable for binding to the AT1R. Bisartan D was synthesized as BisA with Bis alkylation of 2(5) butyl imidazole 3 ( Figure 12 ). The setup was implemented using the YASARA molecular modeling program 53 . The best hits and ligand conformational poses, expressed as kcal/mol free energy of binding, resulting from a minimum of 200 and a maximum of 500 runs were reported. UCSF Chimera and/or Yasara were used to visualize the molecules and the results of the docking and to construct the molecular models 54 .

MD simulations were run with YASARA 55 . The setup included an optimization of the hydrogen bonding network 56 to increase the solute stability, and a pKa prediction to fine-tune the protonation states of protein residues at the chosen pH of 7.4 57 . NaCl ions were added with a physiological concentration of 0.9%, with an excess of either Na or Cl to neutralize the cell. After steepest descent and simulated annealing minimizations to remove clashes, the simulation was run for up to 120 ns using the AMBER14 force field 58 for the solute, GAFF2 59 , and AM1BCC 60 for ligands and TIP3P for water. The cutoff was 8 Å for Van der Waals forces (the default used by AMBER 61 , no cutoff was applied to electrostatic forces (using the Mesh Ewald algorithm 62 ). The equations of motion were integrated with multiple timesteps of 2.5 fs for bonded intermolecular interactions and 5.0 fs for non-bonded interactions at a temperature of 311 O K and a pressure of 1 atm (NPT ensemble) using algorithms described in detail previously 63, 64 . Pharmacological evaluation.

Bisartans and sartans were evaluated in human embryonic kidney (HEK 293) cells which were grown in DMEM/F12 (1:1) containing 3.15 g/L glucose and 10%

bovine calf serum at 37 o C and 5% CO2 (21) . They were also evaluated in iliac arteries as described below.

Male New Zealand White rabbits (n = 4) at 7 weeks of age were purchased Rings were dissected into 2-3 mm rings in preparation for isometric tension analysis.

We 

COVID-19 assay for BisD (tetrazole), BisD (nitrile), and NTV (PF07321332) were carried out by methods previously described 69, 70 . Briefly, the cell culture assay was done as follows. 

GraphPad Prism (version 9) was utilized for statistical analysis of isometric tension data. The significant p-value was set at p < 0.05, and a two-way ANOVA followed by Sidak's multiple comparisons post hoc test was performed to determine significance. All data are represented as mean SEM. ± Figure 1 . Structure (upper left) and electrostatic charge distribution (lower image) of bisartan-A (BisA). Negatively charged regions = red; neutral to positive regions = green to blue. Charge distribution calculated using the RM1 semiempircal method (UHF calculation, total charge = -2.0e, geometry-optimized structure @ 0.1 kcal/mol-Å gradient). Table 1A . (B) Receptor ± switching from an agonist-induced state to a desensitized inverse agonist state. The binding of submaximal doses of ANG II to its receptor induces G protein binding and dimerization of the receptor, a concerted mechanism of positive cooperativity (Hill coefficient nH>1), resulting in an increase in agonist affinity and consequent amplification of the contractile response. Different analogs may invoke different levels of cooperativity (increasing the affinity) when compared to other analogs (e.g. weak or partial agonists). The maximum response may be limited by the available supply of G protein, without which the mode of receptor binding of ANG II at supramaximal doses changes to state#2 and induces negative cooperativity (nH<1) synonymous with inverse agonism (tachyphylaxis). Thus, at high doses, ANG II becomes an inverse agonist, as do other partial agonists 5 . Inverse agonists, such as ARBs, sarilesin, and angiotensin "antipeptides", are unable to activate the receptor, and bind to state#2 forming a salt bridge with Arg167 (shown as --X). The resulting insurmountable "inverted" state of the angiotensin receptor engenders smooth muscle relaxation (vasodilation, via an alternative second messenger) for prolonged periods. This receptor lockdown effect may be due to a slow rate of dissociation of the second messenger. of BisA interacted strongly with the His163 ring via pi-pi resonance (red lines). Tetrazole#1 exhibited no strong interactions, however, the biphenyl groups showed significant hydrophobic interactions (green lines) with several nearby residues, particularly Pro168. BisA did not appear to undergo direct interactions with Cys145, although BisA tetrazole#2 was proximal (3.74Å) to the sulfur atom (large yellow sphere) and therefore probably interacted electrostatically. (B) As was the case for BisA binding, no direct interactions were observed between PF-07321332 and Cys145. However, it is noted that the -CN nitrile group was located proximal to the Cys145 sulfur, which is a potential site of covalent interaction with the ligand. Ligand binding was also marked by a strong hydrogen bond between the nitrile N and the Ser144 -OH. ii) H-bond between OH group of Tyr202 and N atom of bisartan and iii) salt bridges between the second tetrazolate with Arg514. The distance between the second tetrazole and Lys 562 is greater than 5.5 A. It is difficult to support any contact between them. (B) Binding of bisartan A by two Arginines in wild type furin cleavage site (PRRARS) of the spike protein receptor-binding domain. One tetrazole interacts with two R residues (R682 and R683 which is closest to the tetrazole) located in the cleavage site cavity. The third Arg (R685) is oriented in the opposite direction. (C) Binding of bisartan A by three arginines in P681R mutated furin cleavage site (RRRARS) of the spike protein-binding domain. One tetrazole interacts with the three arginine residues R681, R682, and R683, and the second tetrazole with His655. (D) Structures of ARBs losartan (surmountable) and EXP3174 (insurmountable). Onedimensional graphs and (E) Charge relay system in angiotensin II and (F) angiotensin receptor blocker binding to the receptor. (G) Interactions between receptor and olmesartan were determined from the crystal structure. The critical interactions of olmesartan are with R167, W84, Y35, and K199 residues of AT1R. (H) Amino acids at positions 452 (Leu) and 478 (Thr) in spike RBD were replaced by Arginines in the delta variant located at the nearest negatively charged residues (E22, D38, and E35) in ACE2. They also depict the bound bisartan (best bitetrazole binder A) molecule and the zinc atom.

Binding of ARB to angiotensin receptor. The binding of ARB results in a strong salt bridge (hatched bond) with Arg167 (and K199), preventing binding of the receptor to the G protein (which in turn prevents receptor dimerization), and thereby locking the receptor in the inverted state ( Figure 1B ). An alternative second messenger (possibly B-arrestin or a different G protein) binds to the intracellular domain of the receptor leading to inverse agonism (relaxation). Binding and activation of angiotensin II receptor. (B) The conformation of ANG II determined by various spectroscopic techniques is characterized by the presence of a CRS and clustering of the three aromatic rings, including a Phe:His ring:ring interaction. The CRS relays the negative charge at the C-terminus of ANG II to the Tyr hydroxylate, distributing the charge across the CRS, and steering the ANG II molecule to align with two corresponding positive charges (R167 and K199) on the receptor. (C) Salt bridge formation (hatched bond) with R167 and K199 enables an induced fit of key peptide and receptor-based groups, allowing Y35 to H-bond with the imidazole N of His 6 of ANG II. This releases the salt bridge between Tyrosinate 4 of ANG II and R167. Agonist activity may derive from the exchange of the hydroxylate of Tyr 4 of ANG II with that of Y35 of the receptor, releasing the intramolecular charge relay interactions in ANG II and replacing it with an intermolecular interaction with the receptor. These dynamic interactions are transduced by a cooperative mechanism involving G protein binding and receptor dimerization leading to amplification (nH>1 , Table 1B ) of the contractile response. Simultaneous interaction of the aromatic ring of Y35 with the rings of Phe 8 and His 6 of ANG II may be a critical factor in this receptor triggering process, perhaps by aligning Y35 for bonding to the imidazole N of ANG II [NOTE: an aromatic ring has a quadrupole moment which allows it to form a slipped parallel plate or perpendicular plate electrostatic interaction with another ring]. Accordingly, sarilesin, which lacks the necessary aromatic ring for electrostatic interaction with the Y35 ring, is unable to exchange its tyrosinate with that of Y35 and elicit the response. Instead, it maintains a strong salt bridge anchor with R167 rendering sarilesin insurmountable. In contrast, the nonpeptide losartan and the peptide analog sarmesin are surmountable antagonists because they cannot form this salt bridge and form a weaker ion:dipole bond with R167, as does the ANG II TyrOH when released by Y35. (D) Binding of bisartan to the active site zinc atom of ACE2 (E) and R167 of the angiotensin AT1 receptor. 

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Role of a Buried Acid Group in the Mechanism of Action of Chymotrypsin

Rational design, efficient syntheses and biological evaluation of N , N ′-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers

Angiotensin as a model for hormone -receptor interactions

Angiotensin 'antipeptides': (−)messenger RNA complementary to human angiotensin II (+)messenger RNA encodes an angiotensin receptor antagonist

Modeling Substrate Coordination to Zn-Bound Angiotensin Converting Enzyme 2. bioRxiv

Predicting the Reactivity of Nitrile-Carrying Compounds with Cysteine: A Combined Computational and Experimental Study

Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations

Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

Methods for analyzing and interpreting cooperativity in dose-response curves-II. Partial agonists acting on muscarinic receptors in smooth muscle

The relationship between homotropic and heterotropic cooperativity for angiotensin receptors in smooth muscle

Design and Pharmacology of Peptide Mimetics

Tyrosinate fluorescence lifetimes for oxytocin and vasopressin in receptor-simulating environments: Relationship to biological activity and 1H-NMR data

Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential

Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers

Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies

Reply to Letter to the Editor: "Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19

Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review

Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB

Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Targeting the renin−angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges

ACE2: from protection of liver disease to propagation of COVID-19

Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers-Relevance to COVID-19

Distinctive Activation Mechanism for Angiotensin Receptor Revealed by a Synthetic Nanobody

Inhibition of enzymatic degradation of angiotensin II in membrane binding assays: utility of 1,10-phenanthroline

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Mechanism of Ligand Recognition by Human ACE2 Receptor

Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra

Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein

The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets

1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): Clustering of the aromatic rings in dimethylsulfoxide

Role of the NH2-terminal domain of angiotensin II (ANG II) and [Sar1]angiotensin II on conformation and activity. NMR evidence for aromatic ring clustering and peptide backbone folding compared with [des-1,2,3]angiotensin II

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor

Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism

Electronic Sculpting of Ligand-GPCR Subtype Selectivity: The Case of Angiotensin II

New Strategies for Organic Catalysis: The First Highly Enantioselective Organocatalytic Diels−Alder Reaction

Proline-Catalyzed Direct Asymmetric Aldol Reactions

The Proline-Catalyzed Direct Asymmetric Three-Component Mannich Reaction: Scope, Optimization, and Application to the Highly Enantioselective Synthesis of 1,2-Amino Alcohols

The crystal structure of larginine

UCSF Chimera?A visualization system for exploratory research and analysis

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations

Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field

Modeling protein quaternary structure of homo-and hetero-oligomers beyond binary interactions by homology

YASARA View-molecular graphics for all devices-from smartphones to workstations

Assignment of Protonation States in Proteins and Ligands: Combining pKa Prediction with Hydrogen Bonding Network Optimization

Fast empirical pKa prediction by Ewald summation

Simmerling C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB

Development and testing of a general amber force field

Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation

Comparison of multiple Amber force fields and development of improved protein backbone parameters

A smooth particle mesh Ewald method

New ways to boost molecular dynamics simulations

Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions

A New Force Field (ECEPP-05) for Peptides, Proteins, and Organic Molecules

Identifying native-like protein structures with scoring functions based on all-atom ECEPP force fields, implicit solvent models and structure relaxation

Biased Probability Monte Carlo Conformational Searches and Electrostatic Calculations for Peptides and Proteins

PMF Scoring Revisited

Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis

p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication: In silico predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein

writing-original draft preparation

 Tables   Table 1. A) Significance of vasoconstriction in response to cumulative doses of angiotensin II between control, BV6(K + ) 2 , BV6(Na + ), and BV6(TFA) incubations obtained from Figure 1A .

No significance No significance No significance -11. 5 No significance No significance No significance -11.0No significance * p = 0.0493 * p = 0.0186 -10.5 *** p = 0.0002 *** p = 0.0009 *** p = 0.0009 -10.0 **** p < 0.0001 **** p < 0.0001 **** p < 0.0001 -9.5 **** p < 0.0001 **** p < 0.0001 **** p < 0.0001 -9.0 **** p < 0.0001 **** p < 0.0001 **** p < 0.0001 -8.5**** p < 0.0001 **** p < 0.0001 **** p < 0.0001 -8.0 **** p < 0.0001 **** p < 0.0001 **** p < 0.0001 -7.5 **** p < 0.0001 **** p < 0.0001 **** p < 0.0001 -7.0 **** p < 0.0001 **** p < 0.0001 **** p < 0.0001 -6. 5 No significance *** p = 0.0003 * p = 0.0126 -6.0No significance * p = 0.0135 No significance -5. 5 No butyl group at position 2 of the imidazole ring as in losartan. Details of the study are seen in the supplementary material.